Figure 1.

Preparation and characterization of stabilized nanoAH + CpG 1018-adjuvanted formulations of RBD-J by two different approaches (A) Representative particle size distribution profile of untreated (black) and sonicated AH before (red) and after (blue) addition of CpG 1018 as observed by laser diffraction; (B) Representative TEM images of untreated AH (scale bar = 500 nm); (C,D) Representative TEM image of sonicated AH (C) before and (D) after addition of CpG 1018 at doses used in previous mouse studies [13] (scale bar = 500 nm); (E) Linearized Langmuir adsorption isotherm for binding of CpG 1018 to untreated AH; (F) Zeta potential values of untreated AH in presence of increasing concentrations of CpG 1018; (G) Percentage of CpG 1018 remaining unbound to untreated vs. nanoAH at CpG 1018 concentrations greater than Q_max of untreated AH; (H) Representative particle size distribution profiles analyzed by laser diffraction of stabilized (nanoAH + CpG 1018)-adjuvanted formulations of RBD-J prepared using the “higher CpG:Al approach” (F_{Higher CpG 1018: Al}) or the “CpG + PA” approach (F_{CpG 1018 + PA}); see text for details of formulation protocols.